▲ Peaking
Business
Moderna shares soar 60% on melanoma vaccine trial success
Moderna shares surged up to 60% following the reported success of a large-scale melanoma vaccine trial conducted in partnership with Merck.
1 trends tracked about this subject — the full history, oldest to newest below.
Moderna shares surged up to 60% following the reported success of a large-scale melanoma vaccine trial conducted in partnership with Merck.